RxDoctor Payments DataLook up a doctor →

Alton Sartor, MD

Medical Oncology · Rochester, MNNPI 1801877501

Payments from drug & device makers

$5,706,868in general payments, 2019–2025

Across 681 payments — averaging $8380.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$2.8M
  • Merck$1.2M
  • Bayer$516K
  • Novartis$373K
  • AstraZeneca$194K
  • Amgen$184K
  • plus $455K from 37 others
$48,912in research payments, 2019–2025

Across 26 payments — averaging $1881.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$36K
  • Novartis Pharma AG$7K
  • Sanofi-aventis U.S. LLC$4K
  • Sanofi$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,706,868 in reported general payments places this provider in the 90th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$1,346,333
Medicare patients
311
Services billed
48,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →